Drugs / Levodopa-Carbidopa Intestinal Gel
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02549092 | Oct 2015 → May 2020 | Parkinson disease | AbbVie | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-03-29 | AbbVie | Results AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting abbvie.com ↗
Long-term Motor and Non-Motor Symptom Benefits in Patients with Advanced Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal Gel: Final Analysis of the 36-Month DUOGLOBE Real-world Multinational Observational Study |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-03-29 | AbbVie | AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology (AAN) 2022 Annual Meeting abbvie.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Levodopa-Carbidopa Intestinal Gel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02549092 ↗ |